Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz®

Biofrontera AG / Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz® . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• First sales in Belgian market expected in Q1 2015

Continuous progress in approval procedures and clinical trials

Leverkusen, Germany, 26 January 2015 - Biofrontera AG (FSE/AIM: B8F), the biopharmaceutical company focusing on skin cancer, has completed almost all preparations for its launch of Ameluz^® in Belgium.

Pricing has been agreed for the Belgian market and Biofrontera anticipates that it will generate first sales in the first quarter of 2015. It is particularly beneficial that the therapy will be fully reimbursed by the Belgian health care system. An add-on payment, as is required through public health insurance in Germany, will not be required in Belgium. Distribution will be undertaken by Bipharma N.V. which is successfully distributing Ameluz^® in the Netherlands already.

Prof. Hermann Lübbert, CEO of Biofrontera, commented: "Ameluz^® has been well received in Belgium, receiving recognition of the high efficacy and economic viability of the therapy with Ameluz^® for actinic keratosis, also in comparison to competing products. This will not only give us a head-start in Belgium but should also serve as a positive signal towards other markets in Europe".

There is also notable progress in Biofrontera's other activities. During the course of this year, Ameluz^® will be launched in further markets in Europe. More than two thirds of the required 360 patients have been recruited in the Phase III study for the approval of basal cell carcinoma. This study is of great importance for the further growth of Biofrontera in Europe. Preparations for the FDA-filing in the USA are well progressing. All required tests, reports and documents should be finalised within the next eight weeks.

Ends

Enquiries, please contact:

Biofrontera AG Prof. Hermann Lübbert, Chairman of the Management Board Thomas Schaffer, Chief Financial Officer	[phone] [e-mail] www.biofrontera.com
IR Germany: Brainwell Asset Solutions Jürgen Benker	[phone]
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs	[phone]
IR UK: Seton Services Toni Vallen	[phone]
Financial PR: Gable Communications John Bick	[phone] [phone]

Background:

The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz^®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz^® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos^® dermatological range of cosmetics. Belixos^® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos^® cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr. Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1889327

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;